



10/22/03

1644

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants of: Voorberg, et al.

Group Art Unit: 1644

Serial No.: 09/674,752


Examiner: Maher M. Haddad

Filed: December 29, 2000

Docket: 294-86 PCT/US

For: METHOD FOR DIAGNOSIS AND
TREATMENT OF HEMOPHILIA A
PATIENTS WITH AN INHIBITOR

Dated: October 8, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	<i>I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 20231 on October 8, 2003 Dated: 10/8/03</i> 
--	--

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In an Office Action mailed September 10, 2003, the Examiner has imposed a Restriction Requirement to one of the following inventions under the provisions of 35 U.S.C. §121:

- Group I. Claims 17-18, 20, 60-81 and 85-86, drawn to a polypeptide capable of specific binding to factor VIII and interference with the activity of factor VIII inhibitors, which polypeptide comprises the variable part of the heavy chain of a human antibody with factor VIII specificity or a part thereof which at least includes the CDR3 region and a pharmaceutical composition thereof and a method of producing the a recombinant polypeptide antibody.
- Group II. Claim 81, drawn to a pharmaceutical composition for the treatment of factor VIII inhibition comprising a polypeptide that specifically binds an antibody specific for factor VIII.
- Group III. Claims 81-82, drawn to a pharmaceutical composition for the treatment of factor VIII inhibition comprising a polypeptide that specifically

binds an antibody specific for factor VIII and further comprising factor VIII or a compound with factor VIII activity.

- Group IV. Claims 20-21 and 81-82, drawn to a pharmaceutical composition for the treatment of factor VIII inhibition comprising a polypeptide that specifically binds factor VIII and further comprising factor VIII or a compound with factor VIII activity.
- Group V. Claims 19 and 24-57, drawn to a polynucleotide in substantially isolated form, coding for a polypeptide capable of specific binding to factor VIII and interference with the activity of factor VIII inhibitors, which polypeptide comprises the variable part of the heavy chain of a human antibody with factor VIII specificity or a part thereof which at least includes the CDR3 region and a pharmaceutical composition thereof and a kit thereof.
- Group VI. Claims 22 and 83, drawn to a method of treatment of factor VIII inhibition in a human individual comprising administering a polypeptide capable of specific binding to factor VIII and interference with the activity of factor VIII inhibitors, which polypeptide comprises the variable part of the heavy chain of a human antibody with factor VIII specificity or a part thereof which at least includes the CDR3 region and a pharmaceutical composition thereof.
- Group VII. Claim 83, drawn to a method of treatment of factor VIII inhibition in a human individual comprising administering a polypeptide capable of binding an antibody specific to factor VIII.
- Group VIII. Claims 83-84, drawn to a method of treatment of factor VIII inhibition in a human individual comprising administering a polypeptide that specifically binds an antibody specific for factor VIII and further comprising factor VIII or a compound with factor VIII activity.
- Group IX. Claims 23 and 83-84, drawn to a method of treatment of factor VIII inhibition in a human individual comprising a polypeptide that specifically binds factor VIII and further comprising factor VIII or a compound with factor VIII activity.
- Group X. Claims 58-59, drawn to a method for detecting a nucleic acid encoding a human antibody specific for factor VIII, comprising providing a sample containing nucleic acids for testing and contacting the sample with a polynucleotide probe.


In response to the Restriction Requirement, Applicants elect the subject matter defined by the claims of Group I (claims 17-18, 20, 60-81 and 85-86), without traverse.

Applicants reserve the right to pursue the claims of the non-elected Groups in divisional applications.

Applicants were further directed to elect a single disclosed species. Applicants elect species DP-10 in response to this requirement.

It is now believed that this application is in condition for further consideration and examination. If resolution of any remaining issues are required prior to examination of the application, it is respectfully requested that the Examiner contact Applicants' agent at the telephone number provided below.

Respectfully submitted,



Edna I. Gergel, Ph.D.

Reg. No. 50,819

Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, NY 11791
Tel. (516) 822-3550
EIG:jlw
179503_1